Evidence map›Paper›PMID 27713620›Full record

ArticleDrug design, development and therapy2016

Evaluation of effects of various drugs on platelet functions using phorbol 12-myristate 13-acetate-induced megakaryocytic human erythroid leukemia cells.

Tomoki Tada, Kensaku Aki, Wataru Oboshi, Kazuyoshi Kawazoe, Toshiyuki Yasui, Eiji Hosoi

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug design, development and therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Tomoki TadaSubdivision of Biomedical Laboratory Sciences, Graduate School of Health Sciences, Tokushima University.
Kensaku AkiDepartment of Cells and Immunity Analytics, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima.
Wataru OboshiSubdivision of Biomedical Laboratory Sciences, Graduate School of Health Sciences, Tokushima University; Department of Medical Technology, Kagawa Prefectural University of Health Sciences, Kagawa.
Kazuyoshi KawazoeDepartment of Clinical Pharmacy Practice Pedagogy, Institute of Biomedical Sciences.
Toshiyuki YasuiDepartment of Reproductive and Menopausal Medicine, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan.
Eiji HosoiDepartment of Cells and Immunity Analytics, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima.
Tokushima University · JPInstitute of Biomedical Science · GBKagawa Prefectural College of Health Sciences · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe hyperfunction and activation of platelets have been strongly implicated in the development and recurrence of arterial occlusive disease, and various antiplatelet drugs are used to treat and prevent such diseases. New antiplatelet drugs and many other drugs have been developed, but some drugs may have adverse effects on platelet functions.

objectiveThe aim of this study was to establish an evaluation method for evaluating the effect and adverse effect of various drugs on platelet functions. MATERIALS AND

methodsHuman erythroid leukemia (HEL) cells were used after megakaryocytic differentiation with phorbol 12-myristate 13-acetate as an alternative to platelets. Drugs were evaluated by changes in intracellular Ca

resultsThere was a positive correlation between [Ca

conclusionIt is possible to induce HEL cells to differentiate into megakaryocytes, which are a useful model for the study of platelet functions, and the quantification of the inhibition of thrombin-induced increases in [Ca

Indexed as

AspirinBlood PlateletsCilostazolHumansMegakaryocytesPhorbol EstersPlatelet ActivationPlatelet AggregationPlatelet Aggregation InhibitorsPlatelet Function TestsTetradecanoylphorbol AcetateTetrazolesAspirinCilostazolphorbol-12-myristatePhorbol EstersPlatelet Aggregation InhibitorsTetradecanoylphorbol AcetateTetrazolesaspirincilostazolibuprofenintracellular Ca2+ concentration ([Ca2+]i)plateletssodium valproate

Identifiers

PMID27713620
PMCPMC5045028
OpenAlexW2526510295

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.